Merit Medical Systems names Martha Aronson as new CEO

SOUTH JORDAN, Utah - Merit Medical Systems, Inc. (NASDAQ:MMSI), a medical device manufacturer with a market capitalization of $5.38 billion, announced Monday the appointment of Martha Aronson as President and Chief Executive Officer, effective October 3, 2025. Founder Fred Lampropoulos will remain in his current roles until then and continue as Chairman of the Board afterward.

Aronson brings extensive healthcare leadership experience, having previously served as Executive Vice President and President of Global Healthcare for Ecolab, Inc. and Senior Vice President and President of North America for Hill-Rom Holdings, Inc. She also spent nearly 20 years at Medtronic in various leadership positions both in the United States and internationally.

"I am excited to join Merit and truly honored to take on this role," said Aronson. "Fred has built and grown an extraordinary company over the past four decades."

Lampropoulos, who founded Merit in 1987, expressed confidence in the transition: "Martha is uniquely qualified to lead Merit into the future and drive its continued success."

The company also released preliminary unaudited revenue figures for the quarter ended June 30, 2025, projecting approximately $380 to $384 million, representing a 12% to 14% increase compared to the same period in 2024. On a constant currency basis, revenue increased approximately 11% to 13%. According to InvestingPro data, Merit Medical maintains excellent financial health with a strong current ratio of 4.87, though it currently trades at premium valuations relative to earnings growth potential.

Merit Medical develops, manufactures, and distributes disposable medical devices used in interventional, diagnostic, and therapeutic procedures. The company employs approximately 7,300 people worldwide and serves hospitals globally with a sales and clinical support team of more than 800 individuals.

The company plans to release its full financial results for the second quarter on July 30, 2025, according to the press release statement.

In other recent news, Merit Medical Systems, Inc. announced the completion of its acquisition of Biolife Delaware L.L.C. for approximately $120 million in cash and assumed liabilities. This strategic move is expected to contribute $10 to $11 million in revenue for the fiscal year 2025 and is anticipated to be accretive to non-GAAP gross and operating margins in 2025, with further positive effects on earnings per share by 2026. Canaccord Genuity responded to this development by raising its price target for Merit Medical from $108 to $112 while maintaining a Buy rating on the stock.

Additionally, Merit Medical’s WRAPSODY Cell-Impermeable Endoprosthesis (CIE) has received approval from Health Canada, allowing for immediate commercialization in the Canadian market. The device demonstrated superior performance in maintaining primary patency over traditional methods in the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial. Piper Sandler reiterated an Overweight rating with a $110 price target on Merit Medical, despite recent insider sales by executives.

The firm attributed these sales to timing dynamics related to pending mergers and acquisitions, suggesting no risk to the company’s track record of quarterly execution. Merit Medical reaffirmed its full-year 2025 financial guidance, projecting net sales between $1.480 and $1.501 billion, reflecting a 9% to 11% year-over-year increase.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.